AUSTIN, Texas, March 12, 2015—XBiotech announced today that it has launched a website and call center to help patients with metastatic colorectal cancer learn about its U.S. Pivotal Phase III clinical trial. The Phase III study named, XilonixTM Colorectal cancer Immunotherapy Treatment Evaluation (“XCITE”), assesses XBiotech’s True Human™ monoclonal antibody (XilonixTM) for the treatment of metastatic colon cancer.
The website, www.XCITECOLONTRIAL.com provides the locations for all open sites, a pre-screening questionnaire to help individuals determine if they are eligible for the trial, and a call center to answer questions about the trial and site locations.
Total enrollment is expected to consist of 600 patients. The primary objective of the XCITE trial is to assess the ability of XilonixTM to improve the overall survival in patients with metastatic colorectal cancer who have failed standard therapies. XilonixTM contains an anti-inflammatory antibody, which is being tested for its ability to inhibit tumor growth and metastasis by interrupting crucial signals that are necessary for the spread of cancer. In addition, Xilonix™ may help to improve fatigue, muscle loss and anxiety caused from tumor related inflammation.
XBiotech is a leading developer of next generation therapeutic antibodies. The Company is also innovating with manufacturing technology and clinical strategies to lessen capital requirements and reduce lead times for drug development.
About OMNI Health Media:
Originally established in 1996 as a cancer patient education resource, OMNI Health Media (OMNI) has consistently expanded its platform by integrating technologic advances with its health information content, applications and clinical trial services. OMNI has been recognized for producing award-winning, multi-media content which reaches over 1.5 million health information seekers in English, Japanese, and Spanish every month. OMNI currently produces Web applications and health content in oncology, urology, gastroenterology, rheumatology, and women’s health.
The mission of OMNI Health Media is to connect individuals with the most current, comprehensive health information and with others in similar situations. OMNI Health Media also provides services that help cancer patients find appropriate clinical trials evaluating new or novel treatment approaches. OMNI uses a variety of platforms including online, print, video, social media, and live interactive Web chats to connect and empower individuals to better manage their health conditions.
OMNI Health Media produces and manages Women magazine, CancerConnect.com, TheRAConnection.com, aWomensHealth.com and The Web Chats with the Experts interactive series featuring thought leaders from institutions such as Memorial Sloan Kettering, Johns Hopkins, Yale, and other prominent health centers.
Copyright © 2016 CancerConnect. All Rights Reserved.
Tags: Colon Cancer, colorectal cancer, immunotherapy, metastatic colorectal cance, monoclonal antibody, News Tips and Features, News Tips and Features Other, Rectal Cancer, Recurrent/Relapsed Rectal Cancer, Stage IV (D)/Relapsed Colon Cancer, Stage IV Rectal Cancer, xbiotech, xcite
© 1998-2020 theGIconnection.com · All Rights Reserved
The information contained above is general in nature and is not intended as a guide to self-medication by consumers or meant to substitute for advice provided by your own physician or other medical professional. The reader is advised to consult with a physician or other medical professional and to check product information (including packaging inserts) for changes and new information regarding dosage, precautions, and contra indication before administering any drug, herb, supplement, compound, therapy or treatment discussed herein. Neither the editors nor the publisher accepts any responsibility for the accuracy of the information or consequences from the use or misuse of the information contained herein.
Page loaded in 0.490 seconds